PBMs have been increasingly under the regulatory microscope for some time…. and recent focus has never been more intense. The pushback from the industry has also been palpable…. no surprise there….. because there is a lot of $$$s involved with even small changes to the industry model.
While the current election has significantly toned down media attention on PBM healthcare hegemony it is opportune to assess what has happened so far and what changes on the regulatory level can reshape the marketplace.
The article below is thought provoking.
It frames the key issues and lays out some timely questions…..
- How the role of the PBM has changed over time?
- How drug pricing arrangements vary – and also how they don’t?
- Why cross-subsidization of revenue across drug categories is such a big issue and,
- Who are the new players and their connections to the larger system and the value they may bring…..?
……. just to point out a few.
It is fair to say that the outcome of next month’s election…… especially in Congress, may have a major impact on the near term future (and fortunes) of PBMs in the US.
——————————————————————————————–
